Document is current

Article History

Received: 11 November 2024

Accepted: 30 December 2024

First Online: 9 January 2025

Declarations

:

: All procedures performed in this study involving human participants were in accordance with the provisions of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board of Aichi Cancer Center Hospital (No. 2022–0-139).

: The ethics committee waived the need for formal consent from the participants.

: Not applicable.

: Takatsugu Ogata received honoraria from Ono Pharmaceutical Co., Bristol-Myers Squibb, and Taiho Pharmaceutical Co. Yukiya Narita received honoraria and research funds from Ono Pharmaceutical Co., Bristol-Myers Squibb K.K., and Daiichi Sankyo Co., honoraria from Eli Lilly, Yakult Honsha Co., and Taiho Pharmaceutical Co., and research funds from Astrazeneca K.K. Hiroya Taniguchi received honoraria from Ono Pharmaceutical Co. Kenta Murotani received honoraria from Chugai Pharmaceutical Co., Ltd., and Astrazeneca K.K. Yutaka Fujiwara received advisor fees from Daiichi Sankyo Co., honoraria and research funding from AstraZeneca K.K., and research funding from AbbVie G.K., Amgen Inc., AnHeart Therapeutics Inc., Eli Lilly Japan K.K., Incyte, and Merck Sharp & Dohme. Kei Muro received honoraria and research funding from Amgen Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., MSD K.K., and Ono Pharmaceutical Co., and Taiho Pharmaceutical Co. and honoraria from Daiichi Sankyo Co., Bristol-Myers Squibb K.K., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., and research funding from Novartis Pharma K.K., PRA Health Sciences Inc., PARAXEL International Inc., and Sanofi K.K.